

Federal Maritime Commission an application for license as a Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR part 515).

Persons knowing of any reason why the following applicants should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

**Non-Vessel-Operating Common Carrier Ocean Transportation Intermediary Applicants**

Avango Logistics LLC, 552 N York Road, Bensenville, IL 60106, Officers: Konstantin B. Selikhov, Member (Qualifying Individual), Rostislav Chagovets, Member.

**Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicants**

HYH International Cargo Services, Inc., dba H.Y.H. Container Line, 9107 NW 105th Way, Medley, FL 33178, Officer: Hans G. Hofmann, President (Qualifying Individual).

Ocean Star International, Inc., 10880 Wiles Road, Coral Springs, FL 33078, Officer: Joshua S. Morales, President (Qualifying Individual).

Container Loading Solutions International USA, LLC, 755 North Busse Highway, Ste. 217, Bensenville, IL 60106, Officer: Paul J. Gibbs, President (Qualifying Individual).

Fleur De Lis Worldwide LLC, 8302 Shady Ace Lane, Humble, TX 77346, Officer: Julie A. Turpin, President (Qualifying Individual).

Consolcargo USA Inc. dba CSC Consolidators, 10925 NW 27th Street, Ste. 102, Miami, FL 33172, Officers: Rocio D. Lugo, Director (Qualifying Individual), Peter Thomas, Vice President.

A Cargo Inc., 4634 E. Marginal Way S., Ste. C-120, Seattle, WA 98134-2328, Officers: Marcio Fanti, President, Patrick P. Policarpio, Vice President (Qualifying Individuals).

DNIPRO LLC, 645 West 1st Avenue, Roselle, NJ 07203, Officers: Yelena Cherepashenskaya, Manager (Qualifying Individual), Igor Pluta, President.

Target Logistic Services, Inc., 1400 Glenn Curtiss Street, Carson, CA 90746, Officer: Thomas F. Donahue, III, Vice President (Qualifying Individual).

**Ocean Freight Forwarder—Ocean Transportation Intermediary Applicants**

EP Logistics, LLC, 7 Founders Blvd., Ste. E, El Paso, TX 79906, Officer: Octavio Saavedra, Member (Qualifying Individual).  
Concord Express Cargo, Inc., 172-14 119th Avenue, Jamaica Queens, NY 11434, Officers: Christopher E. Okafor, President (Qualifying Individual), Margaret X. Burnes, Secretary.

September 25, 2009.

**Tanga S. FitzGibbon,**

*Assistant Secretary.*

[FR Doc. E9-23568 Filed 9-29-09; 8:45 am]

**BILLING CODE 6730-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the National Coordinator for Health Information Technology**

**HIT Policy Committee Advisory Meeting; Notice of Two-Day Meeting**

**AGENCY:** Office of the National Coordinator for Health Information Technology, HHS.

**ACTION:** Notice of meeting.

This notice announces a forthcoming meeting of a public advisory committee of the Office of the National Coordinator for Health Information Technology (ONC). The meeting will be open to the public.

*Name of Committee:* HIT Policy Committee.

*General Function of the Committee:* To provide recommendations to the National Coordinator on a policy framework for the development and adoption of a nationwide health information technology infrastructure that permits the electronic exchange and use of health information as is consistent with the Federal Health IT Strategic Plan and that includes recommendations on the areas in which standards, implementation specifications, and certification criteria are needed.

*Date and Time:* The two-day meeting will be held on October 27 and October 28, 2009, from 10 a.m. to 5:15 p.m./Eastern Time on October 27th, and 8:30 a.m. to 3 p.m./Eastern Time on October 28th.

*Location:* The Omni Shoreham Hotel, 2500 Calvert Street, NW., Washington, DC. The hotel telephone number is 202-234-0700.

*Contact Person:* Judy Sparrow, Office of the National Coordinator, HHS, 330 C

Street, SW., Washington, DC 20201, 202-205-4528, Fax: 202-690-6079, e-mail: [judy.sparrow@hhs.gov](mailto:judy.sparrow@hhs.gov). Please call the contact person for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.

*Agenda:* The committee will hear presentations from the Meaningful Use, Certification/Adoption, and Information Exchange Workgroups. In addition, invited experts will provide testimony on the mapping of core Meaningful Use objectives and existing measures to medical specialties, small practices, and small hospitals. ONC intends to make background material available to the public no later than two (2) business days prior to the meeting. If ONC is unable to post the background material on its Web site prior to the meeting, it will be made publicly available at the location of the advisory committee meeting, and the background material will be posed on ONC's Web site after the meeting, at <http://healthit.hhs.gov>.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before October 18, 2009. Oral comments from the public will be scheduled approximately 5 p.m./Eastern Time on October 27th, and 12:30 p.m./Eastern Time on October 28th. Time allotted for each public comment is limited to two minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled open public hearing session, ONC will take written comments after the meeting until close of business.

Persons attending ONC's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

ONC welcomes the attendance of the public at its advisory committee meetings. Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Judy Sparrow at least seven (7) days in advance of the meeting.

ONC is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://healthit.hhs.gov> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., App. 2).

Dated: September 24, 2009.

**Judith Sparrow,**

*Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology.*

[FR Doc. E9-23460 Filed 9-29-09; 8:45 am]

BILLING CODE 4150-45-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Availability of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Test Method Evaluation Report: The Reduced Murine Local Lymph Node Assay, an Alternative Test Method Using Fewer Animals To Assess the Allergic Contact Dermatitis Potential of Chemicals and Products; Availability of ICCVAM Recommended Murine Local Lymph Node Assay Performance Standards; Notice of Transmittal to Federal Agencies of ICCVAM Test Method Recommendations for the Reduced Murine Local Lymph Node Assay, Updated Murine Local Lymph Node Assay Test Method Protocol, and Murine Local Lymph Node Assay Test Method Performance Standards**

**AGENCY:** National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH)

**ACTION:** Availability of ICCVAM Test Method Evaluation Report (TMER) and Recommended Test Method Performance Standards; Notice of Transmittal.

**SUMMARY:** NICEATM announces availability of the *ICCVAM Test Method Evaluation Report: The Reduced Murine Local Lymph Node Assay: An Alternative Test Method Using Fewer Animals to Assess the Allergic Contact Dermatitis Potential of Chemicals and Products* (NIH Publication 09-6439). The TMER provides ICCVAM's evaluation and recommendations for the reduced Murine Local Lymph Node Assay (rLLNA) test method as a reduction alternative that uses fewer animals compared to the traditional Murine Local Lymph Node Assay (LLNA) for assessing the potential of test substances to cause allergic contact dermatitis (ACD). The report includes ICCVAM's recommendations on (a) the usefulness and limitations of the

rLLNA, (b) an updated ICCVAM LLNA test method protocol, which includes the procedures for conducting the rLLNA, (c) future studies to further characterize the usefulness and limitations of the rLLNA, and (d) rLLNA test method performance standards. The TMER includes the report of an international independent scientific peer review panel (hereafter, Panel) and the final rLLNA background review document (BRD). The BRD provides the data and analyses used to evaluate the current validation status of the rLLNA test method for assessing the ACD potential of chemicals and products. ICCVAM concluded that the scientific validity of the rLLNA has been adequately evaluated and that the performance of the rLLNA, when conducted in accordance with the ICCVAM-recommended LLNA test method protocol, is sufficient to distinguish between skin sensitizers and non-sensitizers. ICCVAM also concluded that the rLLNA would reduce animal use by 40% for each test compared to the traditional, multi-dose LLNA. Accordingly, ICCVAM recommends that the rLLNA test method should be routinely considered before conducting the traditional, multi-dose LLNA, and used where appropriate as the initial test to determine the potential of chemicals and products to produce ACD. For testing situations that require dose-response information, rLLNA-positive substances will need to be tested with the traditional multi-dose LLNA. This testing should be done using the updated ICCVAM-recommended test method protocol, which reduces animal use by 20% compared to the original ICCVAM-recommended test method protocol by decreasing the minimum number of animals per dose group from five to four.

NICEATM also announces availability of the *ICCVAM Recommended Performance Standards: Murine Local Lymph Node Assay* (NIH Publication 09-7357). The ICCVAM recommends that LLNA test method performance standards can be used to efficiently evaluate the validity of modified versions of the LLNA that are mechanistically and functionally similar to the traditional LLNA. The traditional LLNA test method is the reference test method used as the basis for establishing the LLNA performance standards. The performance standards specify the essential test method components that must be included in a modified LLNA in order to use the performance standards to evaluate the validity of the modified test method.

The performance standards also specify a minimum list of reference substances to evaluate the accuracy and reliability of the modified test method, and the accuracy and reliability values that must be achieved in order for the modified test method to be considered equal to or better than the traditional LLNA.

Electronic copies of the ICCVAM rLLNA TMER and the report on ICCVAM-recommended LLNA performance standards are available from the NICEATM-ICCVAM Web site at <http://iccvam.niehs.nih.gov> or by contacting NICEATM (see **FOR FURTHER INFORMATION CONTACT**). The two reports have been forwarded to U.S. Federal agencies for regulatory and other acceptance considerations, where applicable. Responses will be posted on the NICEATM-ICCVAM website as they are received.

**FOR FURTHER INFORMATION CONTACT:** Dr. William S. Stokes, Director, NICEATM, NIEHS, P.O. Box 12233, Mail Stop: K2-16, Research Triangle Park, NC 27709, (telephone) 919-541-2384, (fax) 919-541-0947, (e-mail) [niceatm@niehs.nih.gov](mailto:niceatm@niehs.nih.gov). Courier address: NICEATM, NIEHS, Room 2034, 530 Davis Drive, Morrisville, NC 27560.

#### **SUPPLEMENTARY INFORMATION:**

##### **Background**

The U.S. Consumer Product Safety Commission (CPSC) nominated several new versions and applications of the LLNA to ICCVAM in 2007 for evaluation of their scientific validity ([http://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC\\_LLNA\\_nom.pdf](http://iccvam.niehs.nih.gov/methods/immunotox/llnadocs/CPSC_LLNA_nom.pdf)). The nomination requested that ICCVAM assess the validation status of: (1) the LLNA limit dose procedure (*i.e.*, the rLLNA); (2) three modified LLNA test method protocols that do not require the use of radioactive materials; (3) the use of the LLNA to test mixtures, aqueous solutions, and metals (applicability domain for the LLNA); and (4) the use of the LLNA to determine ACD potency categories for hazard classification. NICEATM published a **Federal Register** notice (72 FR 27815) requesting public comments on the appropriateness and relative priority of the CPSC-nominated LLNA activities, the development of test method performance standards for the LLNA, the nomination of scientists to serve on the Panel, and the submission of data from LLNA testing that related to the CPSC-nominated LLNA activities, as well as corresponding data from human and other animal studies. After considering public comments and comments from the Scientific Advisory Committee on Alternative Toxicological